Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program

BACKGROUND: Erdafitinib is the first targeted therapy approved for the treatment of patients with metastatic urothelial carcinoma (mUC). Approval was based on a phase II single-arm trial that demonstrated significant activity of erdafitinib in patients with tumors harboring FGFR2/3 alterations. In B...

Descripción completa

Detalles Bibliográficos
Autores principales: Monteiro, Fernando Sabino M., Silva, Adriano Gonçalves e, Gomes, Andrea Juliana P. de S., Dutra, Carolina, Ferreira, Naira Oliveira, Mariano, Rodrigo Coutinho, Schutz, Fabio A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135201/
https://www.ncbi.nlm.nih.gov/pubmed/34046088
http://dx.doi.org/10.1177/17588359211015499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8135201/
https://www.ncbi.nlm.nih.gov/pubmed/34046088
http://dx.doi.org/10.1177/17588359211015499

Ejemplares similares